Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, USA.
J Gastroenterol Hepatol. 2013 Jun;28(6):975-81. doi: 10.1111/jgh.12148.
BACKGROUND AND AIMS: Positron emission tomography with computed tomography (PET/CT) has been used to detect metastasis in the diagnosis of esophageal adenocarcinoma (EAC). However, the utility of PET/CT to assess primary tumor for endoscopic resectability and prognosis in early EAC remains unclear. We conducted a retrospective study to determine the association of PET/CT findings with histopathological tumor invasion depth and survival outcomes. METHODS: EAC patients who underwent PET/CT followed by endoscopic mucosal resection (EMR) were included. Pathology on EMR and survival outcomes from a prospectively maintained database was retrieved. Two radiologists independently reviewed the PET/CT using the following parameters: detection of malignancy, fluorodeoxyglucose (FDG) uptake intensity, FDG focality, FDG eccentricity, esophageal thickness, maximal standard uptake value (SUVmax), and SUVmax ratio (lesion/liver). RESULTS: There were 72 eligible patients: 42 (58.3%) had T1a lesions, and 30 (41.7%) had ≥ T1b. Only SUVmax ratio was associated with tumor invasion depth (odds ratio=2.77, 95% confidence interval 1.26-7.73, P=0.0075). Using a cut-off of 1.48, the sensitivity and specificity of SUVmax ratio for identification of T1a lesions were 43.3% and 80.9%, respectively. Adjusting the SUVmax ratio to 2.14, 16.7% (5/30) of ≥ T1b patients were identified without any false-positive cases. Multivariate analysis showed SUVmax ratio, Charlson comorbidity index, and esophagectomy were independent predictors for survival. CONCLUSIONS: SUVmax ratio (lesion/liver) is more accurate in predicting endoscopic resectability and mortality for EAC than other PET/CT parameters and appears promising as a useful adjunct to the current diagnostic work-up.
背景与目的:正电子发射断层扫描与计算机断层扫描(PET/CT)已用于诊断食管腺癌(EAC)中转移的检测。然而,PET/CT 用于评估早期 EAC 原发肿瘤的内镜可切除性和预后的效用尚不清楚。我们进行了一项回顾性研究,以确定 PET/CT 结果与组织病理学肿瘤浸润深度和生存结果的关系。
方法:纳入接受 PET/CT 检查后行内镜黏膜切除术(EMR)的 EAC 患者。从前瞻性维护的数据库中检索 EMR 病理和生存结果。两名放射科医生使用以下参数独立审查 PET/CT:恶性肿瘤的检测、氟脱氧葡萄糖(FDG)摄取强度、FDG 局灶性、FDG 偏心性、食管厚度、最大标准摄取值(SUVmax)和 SUVmax 比值(病变/肝脏)。
结果:共有 72 例符合条件的患者:42 例(58.3%)为 T1a 病变,30 例(41.7%)为≥T1b。只有 SUVmax 比值与肿瘤浸润深度相关(优势比=2.77,95%置信区间 1.26-7.73,P=0.0075)。使用 1.48 的截断值,SUVmax 比值对 T1a 病变的识别的灵敏度和特异性分别为 43.3%和 80.9%。将 SUVmax 比值调整为 2.14 时,30 例≥T1b 患者中有 16.7%(5/30)被识别,且无假阳性病例。多变量分析显示,SUVmax 比值、Charlson 合并症指数和食管切除术是生存的独立预测因素。
结论:SUVmax 比值(病变/肝脏)比其他 PET/CT 参数更能准确预测 EAC 的内镜可切除性和死亡率,并且作为当前诊断性检查的有用辅助手段具有很大的前景。
J Thorac Cardiovasc Surg. 2000-12
Gastrointest Endosc. 2011-10-13
World J Gastroenterol. 2016-12-21
Gastroenterology. 2015-8
Cancers (Basel). 2014-9-29
World J Gastrointest Oncol. 2014-8-15